Australija - anglų - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 426.6 mg (equivalent: lidocaine hydrochloride, qty 400 mg) - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections; sodium hydroxide - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 106.65 mg (equivalent: lidocaine hydrochloride, qty 100 mg) - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - bupivacaine hydrochloride, quantity: 1.25 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 1.32 mg/ml); fentanyl citrate, quantity: 7.9 microgram/ml (equivalent: fentanyl, qty 5 microgram/ml) - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - marcain 0.125% with fentanyl is intended for post-operative or obstetric epidural analgesia.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 250 microgram - tablet, uncoated - excipient ingredients: magnesium stearate; rice starch; lactose monohydrate; oxidised maize starch; hydrolysed maize starch - congestive heart failure - sigmaxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. sigmaxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because sigmaxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - sigmaxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 0.0625 microgram - tablet, uncoated - excipient ingredients: lactose monohydrate; rice starch; magnesium stearate; hydrolysed maize starch; povidone; indigo carmine; oxidised maize starch - congestive heart failure - sigmaxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. sigmaxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because sigmaxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - sigmaxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 20 mg/ml; adrenaline (epinephrine) acid tartrate, quantity: 22.7 microgram/ml (equivalent: adrenaline (epinephrine), qty microgram/ml) - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; sodium chloride; hydrochloric acid; sodium hydroxide - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - bupivacaine hydrochloride, quantity: 3.75 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 3.96 mg/ml) - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; water for injections - indications as at 4 april 2000: marcain solutions are indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia - epidural block for surgery, field block (minor and major nerve blocks and infiltration). analgesia - continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. - field block (minor nerve block and infiltration). the choice of 4 strengths, 0.125%, 0.25%, 0.375% and 0.5%, makes it possible to vary the degree of motor blockade.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - bupivacaine hydrochloride, quantity: 2.5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 2.64 mg/ml) - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - indications as at 4 april 2000: marcain solutions are indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia - epidural block for surgery, field block (minor and major nerve blocks and infiltration). analgesia - continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. - field block (minor nerve block and infiltration). the choice of 4 strengths, 0.125%, 0.25%, 0.375% and 0.5%, makes it possible to vary the degree of motor blockade.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - bupivacaine hydrochloride, quantity: 1.25 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 1.32 mg/ml) - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - marcain solutions are indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia - epidural block for surgery, field block (minor and major nerve blocks and infiltration). analgesia - continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. - field block (minor nerve block and infiltration). the choice of 4 strengths, 0.125%, 0.25%, 0.375% and 0.5%, makes it possible to vary the degree of motor blockade.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - phenytoin sodium, quantity: 250 mg - injection, solution - excipient ingredients: propylene glycol; water for injections; hydrochloric acid; sodium hydroxide; ethanol absolute - for the control of status epilepticus, tonic-clonic (grand mal), psychomotor seizures and the prevention of seizures occurring during or following neurosurgery. phenytoin will prevent or effectively decrease the incidence and severity of convulsive seizures in a high percentage of cases, with patients exhibiting little tendency to become resistant to its action. besides its effectiveness in controlling seizures, phenytoin frequently improves the mental condition and outlook of epileptic patients. it has also been used in the treatment of certain cardiac arrhythmias, particularly in those patients who do not respond to conventional antiarrhythmic agents or to cardioversion. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administration)